ATAI News and Press, ATAI Life Sciences N.V. From 08/03/21

An increasing number of cities are considering reforming laws that would effectively decriminalize the use of psychedelic drugs for recreational use, Marijuana Moment reports. The latest cities to consider such measures include Easthampton, Mass.; Grand Rapids, Mich.; and Arcata, Calif. Refor...

BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest , ...

NetworkNewsWire Editorial Coverage : In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may have treatment advantages over existing th...

The obesity epidemic in the U.S. is only getting worse. In fact, by the time 2030 rolls around, nearly half of all U.S. adults are projected to be obese, according to Harvard researchers, as noted by MSN. While some companies have suggested using “magnets cemented to your teeth to st...

Moha El-Jaw/iStock via Getty Images "Magic mushrooms," LSD, and MDMA, once thought to be purely recreational drugs, are under investigation by many publicly traded companies as potential psychedelic treatments for a range of diseases. An increasing amount of research is demonstrating that the...

ATAI Life Sciences N.V (ATAI), Compass Pathways Plc (CMPS), and Mind Medicine Holdings (MNMD) are 3 stocks that are looking to commercialize psychedelics for medical use. Investors should keep them on their radars as they have massive long-term potential. Norms and regulations in society...

Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis Palo Santo's Commitment to Help Fund a New Paradigm in Wellbeing PR Newswire CHICAGO , July 15, 2021 /PRNewswire/ -- P ...

adrian825/iStock via Getty Images Psychedelic drug developers started as buys Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald have initiated Atai Life Sciences ([[ATAI]] +2.3%) with  buy/overweight ratings. Credit Suisse has a $25 price target on shares (~35% upside) Credit...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 17, 2021 –  What was once a war on drugs has turned into a public push for the decriminalization and legalization of illegal drugs with potential therapeutic benefits. Leg...

BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced that it will present and p...